Objective
Though survival of children with acute lymphoblastic leukaemia (ALL) has improved, relapse remains a leading cause of mortality in childhood cancer. Given the rarity of the disease, only a large international cooperative group can recruit sufficient patients for prospective studies with specific questions in biologic subgroups. Under the umbrella of the I-BFM SG all relevant mainly European study groups are creating the worldwide largest Study for Children with Relapsed ALL (IntReALL 2010). The aim is to develop optimized standard treatment as platform for systematic randomized phase II and III studies on the most promising new and targeted agents. An adequate trial structure, an optimized web based database, and standardized diagnostic methods need to be established.
Patients are stratified into a standard (SR) and a high risk (HR) group according to established factors. For SR patients, the best available treatment protocols ALL-REZ BFM 2002 and ALL R3 are randomly compared, and the additional effect on survival of the humanized monoclonal CD22 directed antibody epratuzumab is investigated. HR patients who have unsatisfying remission rates will receive an intensified induction with the proteasome inhibitor bortezomib randomly combined with standard induction therapy. IntReALL 2010 allows for comprehensive tumour banking and systematic biologic research in subgroups with correlation to clinical outcome. SMEs will be involved into project management, data base development, and pharmaceutical and biotechnological research to ensure innovation in the respective areas. IntReALL 2010 is embedded in a network of European academic structures relevant for childhood cancer. It will be a cornerstone of drug development in childhood leukaemia and the only trial with the potential for well powered phase III studies in this indication. IntReALL 2010 will harmonize ALL-relapse therapy, establish highest diagnostic and therapeutic standard and improve survival of children with ALL.
Fields of science
Call for proposal
FP7-HEALTH-2011-two-stage
See other projects for this call
Funding Scheme
CP-FP - Small or medium-scale focused research projectCoordinator
10117 Berlin
Germany
See on map
Participants (28)
8006 Zurich
See on map
150 06 Praha 5
See on map
1090 Wien
See on map
Participation ended
25030 BESANCON CEDEX
See on map
1099 023 Lisboa
See on map
1020 BRUXELLES
See on map
17177 Stockholm
See on map
3400 Hillerod
See on map
20520 Turku
See on map
0450 Oslo
See on map
M13 9PL Manchester
See on map
Participation ended
6525 XZ Nijmegen
See on map
00165 Roma
See on map
64239 Tel Aviv
See on map
50 367 Wroclaw
See on map
Participation ended
46015 VALENCIA
See on map
1018 RG Amsterdam
See on map
OX1 2JD Oxford
See on map
30625 Hannover
See on map
07950 Morris Plains
See on map
80335 MUNCHEN
See on map
Participation ended
CB22 3AT CAMBRIDGE
See on map
10117 BERLIN
See on map
1200 Bruxelles / Brussel
See on map
Participation ended
2333 BZ LEIDEN
See on map
06003 Nice
See on map
3584CS Utrecht
See on map
2333 BZ Leiden
See on map